HANEY CECIL D sold (to issuer) $86K of THC

HANEY CECIL D sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · HANEY CECIL D
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure updates insider ownership but does not include any operational, regulatory, or financial developments for Tenet Healthcare.

02

Market read

Traders may briefly reassess sentiment around THC due to insider selling, but the event lacks fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the transaction code D (sale to issuer) can still be non-informational; watch for subsequent insider buys/sales or larger institutional changes.

Relevance 6/10Timing: Filing dated 2026-05-26 for a transaction on 2026-05-22; impact, if any, is most relevant around the filing window.

Background

SEC Form 4 discloses insider transactions; code D indicates sale to the issuer (e.g., buyback participation).

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Haney Cecil D sold 493 shares to the issuer for about $85.7K at $173.78/share, per SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely small and short-lived unless follow-on filings show broader selling.

Evidence & confidence

Single director transaction size is small versus typical market moves, and the filing provides no new company-specific operating or financial information.

Market effects

No clear read-through to healthcare sector fundamentals from a single director Form 4 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is to the issuer (often tied to buyback/plan mechanics), it may reflect routine liquidity or corporate action rather than bearish expectations.

Key entities

  • Tenet Healthcare Corp

    Company whose director insider transaction was reported on SEC Form 4.

  • Haney Cecil D

    Tenet Healthcare director who sold 493 shares to the issuer on 2026-05-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.